Prescribing Behavior

Picture and promise lower antibiotic Rx

Researchers found that a signed promise not to prescribe lowered prescriptions by around 20%.

CVS joins prescription crackdown

By

The drugstore chain says it has cut off over-prescribers of tightly controlled medications.

Study finds docs suceptible to lunches, patient demands for branded drugs

By

Internists and small-office practitioners are also more likely to prescribe branded drugs than their professional peers.

MPR gets new look, adds e-prescriptions

By

Monthly Prescribing Reference's first revamp in three years includes new features which have already attracted new users. VP of product development Tammy Chernin told MM&M these changes are just the beginning.

Company news: GlaxoSmithKline, DIA and PDR Network

The DIA and the Healthcare Businesswomen's Association formalized a multi-year partnership, and GSK began shipping vaccine for the 2012-2013 flu season

"Digital divide" between old and young docs narrowing, survey finds

By

Three out of five doctors are now using technology to better communicate with patients, a MedPage Today survey has found, and two-fifths say patients are generally more informed than they were five years ago.

E-prescriptions boost adherence data

By

A new study by Surescripts, the nation's largest e-prescription network, suggests that saving patients the trouble of toting a prescription to a store increases the likelihood that they will get it filled and take their meds.

Study shows prescription gender gap

By

Women are simultaneously given more drugs than men and undertreated, according to a study Medco and the Society of Women's Health Research.

Consumers anxious about drug costs, industry influence

By

A fifth of consumers have asked their doctor to prescribe a drug they learned about through advertising, and fully two-thirds have received free samples of prescription drugs from their doctor - but they worry about the industry's influence on physicians, according to a Consumer Reports survey.

Prescriber data law in Maine headed for federal court

Prescriber data law in Maine headed for federal court

By

A federal appeals court will hear oral arguments regarding Maine's prescription data law, which allows physicians to "opt-out" of commercially traded data pertaining to their prescribing habits.

Abbott's next step for Niaspan

Abbott's next step for Niaspan

By

Abbott Labs' cholesterol drug Niaspan is growing prescription share nicely after a clinical trial highlighted its potential as part of a one-two punch in reducing plaque. Now, the company says, it is considering how best to capitalize on the data.

ARBITER leaves some lasting marks on Merck

ARBITER leaves some lasting marks on Merck

By

The nature and amount of press coverage is often a key factor in assessing how clinical trial results impact a product's prescription trends. In the case of the ARBITER 6-HALTS trial, Merck's cholesterol franchise has benefited from largely balanced coverage, somewhat limiting damage to lipid drugs Zetia and Vytorin.

Slow diagnosis hampers uptake of fibromyalgia drugs

Slow diagnosis hampers uptake of fibromyalgia drugs

By

As the number of FDA-approved fibromyalgia therapies has grown, so has patient hope. However, the condition is still not well understood by the medical community overall, hampering uptake of branded drugs approved for the disorder.

DTC ads made some cancer patients doubt their docs

By

A survey of patients at Harvard's Dana-Farber Cancer Institute found that 11% said ads for cancer-related drugs had made them less confident in their providers' judgment.

Predicting Product Launch Success: An Ace in the Whole

Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions

Email Newsletters

MM&M inVISION